文献速递临床免疫分子诊断

新型全自动Lumipulse免疫分析法定量血浆APOE4可识别纯合与杂合ε4携带状态

Quantification of plasma APOE4 with a novel automated Lumipulse immunoassay enables the identification of homozygous and heterozygous APOE ε4 carrier status.
PubMed 文献 · Clin Chim Acta · 2025-10-12

本研究评估新型全自动免疫分析法定量血浆APOE4与总APOE(Pan-APOE)的准确性及临床效用。对65例不同APOE ε4基因型患者血浆检测,APOE4/Pan-APOE比值(Ratio%)在组间无重叠,ROC曲线AUC为1.00,14% cut-off下灵敏度和特异度均为100%,与基因检测完全一致(Cohen's kappa=1.00)。

要点

  • 血浆APOE4/Pan-APOE Ratio%可区分ε4携带状态,组间无重叠。
  • 14% cut-off下识别ε4携带者的灵敏度和特异度均为100%。
  • 免疫分析法与基因检测结果完全一致(kappa=1.00)。

核心结论

  • 新型全自动Lumipulse免疫分析法定量血浆APOE4和Pan-APOE可准确识别APOE ε4纯合与杂合携带状态。

研究设计与样本

  • 研究纳入65例患者血浆样本,其中39例ε4非携带者、21例ε4杂合子、5例ε4纯合子。
  • 采用Lumipulse 1200 G APOE4与Pan-APOE免疫分析法检测,计算APOE4/Pan-APOE比值(Ratio%),并与基因检测比较。
  • 使用三例不同基因型患者的三重复测量评估实验重复性。

主要发现

  • APOE4和Pan-APOE蛋白水平及Ratio%在ε4状态组间差异显著(p < 0.0001)。
  • Ratio%在组间无重叠。
  • ROC曲线分析识别ε4携带者的AUC为1.00,14% cut-off下灵敏度和特异度均为100%。
  • 免疫分析法与基因检测完全一致(Cohen's kappa = 1.00,p < 0.0001)。
  • APOE4的批内CV <5%,Ratio%的批内CV <8%。

关键数值与推荐

  • APOE4/Pan-APOE Ratio%的14% cut-off用于识别ε4携带者,灵敏度和特异度均为100%。
  • 免疫分析法与基因检测一致性Cohen's kappa = 1.00(p < 0.0001)。

临床怎么用

  • 该免疫分析法有望提供更快速的结果,在临床实践中尤其利于阿尔茨海默病治疗资格评估。
  • 在广泛临床实施前,需在更大规模、多样化队列中进一步验证。

局限性

  • 研究样本量较小(65例),需在更大、多样化队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Apolipoprotein E (APOE) ε4 allele is a significant risk factor for Alzheimer's disease (AD). While genetic testing remains the gold standard for determining APOE status, protein-level quantification could offer advantages in clinical practice. This study evaluates a novel, fully automated immunoassay for quantifying APOE4 and total APOE (Pan-APOE) in plasma samples, assessing its accuracy and clinical utility compared to traditional genetic testing. MATERIALS AND METHODS: Plasma samples from 65 patients (39 ε4 non-carriers, 21 ε4 heterozygous, 5 ε4 homozygous) were analyzed using the Lumipulse 1200 G APOE4 & Pan-APOE immunoassays. The APOE4/Pan-APOE ratio (Ratio%) was calculated to determine ε4 carrier status. Results were compared to genetic testing. Assay repeatability was evaluated using triplicate measurements from three patients with different genotypes. RESULTS: APOE4 and Pan-APOE protein levels and Ratio% differed significantly across ε4 status groups (p < 0.0001). The Ratio% showed no overlap between groups. ROC curve analysis for ε4 carrier identification showed an AUC of 1.00, with 100 % sensitivity and specificity at a 14 % cut-off. Perfect agreement was observed between the immunoassay and genetic testing (Cohen's kappa = 1.00, p < 0.0001). Intra-assay CV was <5 % for APOE4 and <8 % for Ratio%. DISCUSSION: This novel immunoassay demonstrates excellent and potential for faster results could offer advantages in clinical practice, particularly for AD therapy eligibility evaluation. However, further validation in larger, diverse cohorts is necessary before considering widespread clinical implementation.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Musso G, Cosma C, Moz S, et al. Quantification of plasma APOE4 with a novel automated Lumipulse immunoassay enables the identification of homozygous and heterozygous APOE ε4 carrier status. Clin Chim Acta. 2025. PMID: 41086898. doi:10.1016/j.cca.2025.120659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。